XBI is trading 3.32% down at $158.82 amid broader biotech sector pressure and a shift toward softer risk sentiment.
- The decline follows a weak open for biotech names and appears to be driven by profit-taking after the ETF's recent rally.
- No company-specific catalyst was identified for the move, which outpaces the slight decline seen in the broader Nasdaq index.